Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 28,323 Vera Therapeutics, Inc. $VERA

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 28,323 shares of the company’s stock, valued at approximately $1,434,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Vera Therapeutics by 14.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,624 shares of the company’s stock worth $943,000 after acquiring an additional 2,391 shares during the period. Berkshire Money Management Inc. bought a new position in shares of Vera Therapeutics during the 4th quarter worth $253,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Vera Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after acquiring an additional 639 shares during the period. AMI Asset Management Corp bought a new position in shares of Vera Therapeutics during the 4th quarter worth $1,444,000. Finally, Perigon Wealth Management LLC grew its stake in shares of Vera Therapeutics by 11.6% during the 4th quarter. Perigon Wealth Management LLC now owns 14,396 shares of the company’s stock worth $729,000 after acquiring an additional 1,498 shares during the period. Institutional investors own 99.21% of the company’s stock.

Insider Activity

In other news, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer directly owned 114,181 shares in the company, valued at $4,793,318.38. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO David Lee Johnson sold 2,579 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the sale, the chief operating officer owned 45,727 shares in the company, valued at approximately $1,919,619.46. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 56,441 shares of company stock valued at $2,416,902. 15.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on VERA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Finally, HC Wainwright increased their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $81.45.

Vera Therapeutics Trading Down 1.2%

Shares of VERA opened at $35.20 on Friday. The business’s 50-day moving average price is $40.34 and its 200-day moving average price is $40.18. Vera Therapeutics, Inc. has a twelve month low of $18.76 and a twelve month high of $56.05. The stock has a market cap of $2.51 billion, a PE ratio of -7.55 and a beta of 0.96. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the previous year, the company posted ($0.72) earnings per share. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -5.33 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.